Contraindicated (one)bortezomib will raise the stage or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or reasonable CYP2C19 inhibitors may perhaps boost mavacamten systemic publicity, causing heart failure as a consequence of systolic dysfunction. Screen for hepatitis B virus in all most cancers patients starting off systemic https://abbak665whs8.wikissl.com/user